Assessing the Efficacy of Desvenlafaxine for Improving Functioning and Well-Being Outcome Measures in Patients With Major Depressive Disorder

Abstract

Desvenlafaxine therapy resulted in significant improvements in the functioning and well-being among MDD patients.

Symptomatic and Functional Improvement in Employed Depressed Patients

“…32 However, in the current study, the mean difference scores in the ITT population for the SDS Social and Family items and the SDS total score were not significantly different from placebo and were smaller in magnitude than those observed in the pooled analysis. In contrast, among the mITT population, the adjusted mean differences in the SDS total and all SDS subitems were superior for desvenlafaxine-versus placebo-treated patients.…”

“…These results are consistent with previously conducted desvenlafaxine clinical trials that used MDD patients without considering employment status. 31,32 The observed differences in HAM-D 17 total score of 2.1 in the ITT population and 2.6 in the mITT population do not reach the threshold of 3.0 for a clinically significant change, which has been proposed by the National Institute of Clinical Excellence. 33 In the current study, placebo response was quite robust, as evidenced by the response (42%) and remission (32%) rates for the ITT population.…”

The effect of vortioxetine on overall patient functioning in patients with major depressive disorder

“…The SDS is a validated measure of functional impairment that has demonstrated sensitivity to impairment and the effects of treatment across a wide range of disorders, including MDD (Sheehan & Sheehan, 2008). The SDS has been used to assess functional improvement in association with improvements in depressive symptoms for duloxetine (Mancini et al., 2012; Oakes et al., 2012; Sheehan et al., 2011; Wise et al., 2008), desvenlafaxine (Dunlop et al., 2011; Guico‐Pabia et al., 2012; Soares et al., 2009), paroxetine (Wise et al., 2008), bupropion (Hewett et al., 2010; Soczynska et al., 2014), escitalopram (Romera et al., 2012; Soczynska et al., 2014), venlafaxine (Fann et al., 2015; Hewett et al., 2010), levomilnacipran (Asnis et al., 2013; Sambunaris, Bose, et al., 2014), and agomelatine (Montgomery, Nielsen, et al., 2014; Zajecka et al., 2010) with results that have been variable with respect to clinical significance; however, many of these antidepressants showed significant differences versus placebo in the change from baseline versus placebo in the SDS total score when patients were stratified by baseline depressive symptom severity. A recent pooled analysis showed that treatment with duloxetine ( n  = 1,029) and SSRIs ( n  = 835) resulted in significantly greater improvements in the SDS total score (∆ −1.9, p  <   .001; ∆ −1.7, p  <   .01, respectively) compared to placebo ( n  = 329).…”

Meta-analyses with industry involvement are massively published and report no caveats for antidepressants

“…A C C E P T E D ACCEPTED MANUSCRIPT Soares 2009 Desvenlafaxine therapy resulted in significant improvements in functioning and well-being among MDD patients.…”